Lectin-like oxidized LDL receptor 1 is involved in CRP-mediated complement activation

Clinical Chemistry

Volumn 57, Issue 10, 2011, Pages 1398-1405

  Fujita, Yoshiko ^a   Yamaguchi, Saburo ^a   Kakino, Akemi ^a   Iwamoto, Shin ^a   Yoshimoto, Ryo ^a   Sawamura, Tatsuya ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCIUM ION; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3D; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PHOSPHORYLCHOLINE; RECEPTOR ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL INFILTRATION; CHO CELL; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT FIXATION; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; LEUKOCYTE; MALE; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN IMMOBILIZATION; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALS; ANTIBODIES; C-REACTIVE PROTEIN; CELL-FREE SYSTEM; CHO CELLS; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C3D; CRICETINAE; CRICETULUS; HUMANS; IMMOBILIZED PROTEINS; MALE; NEUTROPHIL INFILTRATION; PHOSPHORYLCHOLINE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECOMBINANT PROTEINS; SCAVENGER RECEPTORS, CLASS E; SKIN;

RATTUS;

EID: 80053418974     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.168625     Document Type: Article

References (40)

1. Volanakis JE, Kaplan MH. Interaction of Creactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol 1974;113:9-17.
2. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-90. (Pubitemid 39625721)
3. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54. (Pubitemid 29084777)
4. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taylor AA, Smith CW. Inflammation in the course of early myocardial ischemia. FASEB J 1991;5:2529-37. (Pubitemid 21905802)
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43. (Pubitemid 34212626)
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. (Pubitemid 27152782)
7. Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, et al. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol 2005;167:1139-48. (Pubitemid 41416264)
8. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006;113:2128-34; discussion 51.
9. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
10. Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: part II. Circulation 2003;108:2041-8. (Pubitemid 37337575)
11. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006;113:2135-50; discussion 50.
12. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647-55. (Pubitemid 38198873)
13. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 2005;102:8309-14. (Pubitemid 40800085)
14. Trion A, De Maat MP, Jukema JW, van der Laarse A, Maas MC, Offerman EH, et al. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-Leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 2005;25:1635-40. (Pubitemid 41098933)
15. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97-103. (Pubitemid 27029949)
16. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999;190:1733-40.
17. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-21.
18. Nijmeijer R, Lagrand WK, Lubbers YT, Visser CA, Meijer CJ, Niessen HW, Hack CE. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol 2003;163:269-75. (Pubitemid 36759611)
19. Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, et al. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 2009;55:285-94.
20. Fujita Y, Kakino A, Harada-Shiba M, Sato Y, Otsui K, Yoshimoto R, Sawamura T. C-reactive protein uptake by macrophage cell line via class-A scavenger receptor. Clin Chem 2010;56:478-81.
21. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-7. (Pubitemid 27130922)
22. Inoue K, Arai Y, Kurihara H, Kita T, Sawamura T. Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ Res 2005;97:176-84. (Pubitemid 41033474)
23. Hinagata J, Kakutani M, Fujii T, Naruko T, Inoue N, Fujita Y, et al. Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model. Cardiovasc Res 2006;69:263-71. (Pubitemid 41814827)
24. Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007;100:1634-42. (Pubitemid 46897266)
25. Yao EH, Fukuda N, Ueno T, Matsuda H, Matsumoto K, Nagase H, et al. Novel gene silencer pyrrole-imidazole polyamide targeting lectin-like oxidized low-density lipoprotein receptor-1 attenuates restenosis of the artery after injury. Hypertension 2008;52:86-92.
26. Li D, Williams V, Liu L, Chen H, Sawamura T, Antakli T, Mehta JL. LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation. Am J Physiol Heart Circ Physiol 2002;283:H1795-801. (Pubitemid 35217012)
27. Kataoka K, Hasegawa K, Sawamura T, Fujita M, Yanazume T, Iwai-Kanai E, et al. LOX-1 pathway affects the extent of myocardial ischemiareperfusion injury. Biochem Biophys Res Commun 2003;300:656-60. (Pubitemid 36268886)
28. Hu C, Chen J, Dandapat A, Fujita Y, Inoue N, Kawase Y, et al. LOX-1 abrogation reduces myocardial ischemia-reperfusion injury in mice. J Mol Cell Cardiol 2008;44:76-83.
29. Kakutani M, Ueda M, Naruko T, Masaki T, Sawamura T. Accumulation of LOX-1 ligand in plasma and atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits: identification by a novel enzyme immunoassay. Biochem Biophys Res Commun 2001;282:180-5. (Pubitemid 32924362)
30. Nagase M, Hirose S, Sawamura T, Masaki T, Fujita T. Enhanced expression of endothelial oxidized lowdensity lipoprotein receptor (LOX-1) in hypertensive rats. Biochem Biophys Res Commun 1997;237:496-8. (Pubitemid 27434712)
31. Honjo M, Nakamura K, Yamashiro K, Kiryu J, Tanihara H, McEvoy LM, et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci U S A 2003;100:1274-9. (Pubitemid 36183992)
32. Roux KH, Kilpatrick JM, Volanakis JE, Kearney JF. Localization of the phosphocholine-binding sites on C-reactive protein by immunoelectron microscopy. J Immunol 1983;131:2411-5. (Pubitemid 14227444)
33. Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007;50:1115-22. (Pubitemid 47375011)
34. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 2008;456:989-92.
35. Bang R, Marnell L, Mold C, Stein MP, Clos KT, Chivington-Buck C, Clos TW. Analysis of binding sites in human C-reactive protein for FcgammaRI, FcgammaRIIA, and C1q by site-directed mutagenesis. J Biol Chem 2005;280:25095-102. (Pubitemid 40934601)
36. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005;2:29-36; quiz 58.
37. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 1999;163:3957-62. (Pubitemid 29450924)
38. Biro A, Rovo Z, Papp D, Cervenak L, Varga L, Fust G, et al. Studies on the interactions between C-reactive protein and complement proteins. Immunology 2007;121:40-50. (Pubitemid 46537662)
39. Lauver DA, Lockwood SF, Lucchesi BR. Disodium disuccinate astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. J Pharmacol Exp Ther 2005;314:686-92. (Pubitemid 41043850)
40. Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 2004;95:877-83. (Pubitemid 39435002)